School of Chemical and Biomedical Engineering, Nanyang Technological University, 62 Nanyang Drive, Singapore 637459, Singapore.
J Proteomics. 2010 May 7;73(7):1283-90. doi: 10.1016/j.jprot.2010.02.016. Epub 2010 Feb 24.
The development of hepatocellular carcinoma (HCC) can be considered as an end-stage outcome of chronic hepatitis B virus (HBV) infection. Early prognostic markers are needed to allow effective treatments and prevent HCC from developing. Proteomics analysis has been used to identify markers from clinical samples from HCC patients. This approach can be further improved by identifying early biomarkers before the onset of HCC. One way would be to use the cell-based HBV replication system, which is reflective of the early stage of virus infection and thus secreted proteins identified at this stage may have relevance in HCC prognosis. In this review, we focus the discussion on the current status of proteomics analysis of cellular proteins and HCC biomarker identification, with a special highlight on the potential of the cell-based HBV replication system for the identification of prognostic HCC biomarkers.
肝细胞癌 (HCC) 的发展可以被视为慢性乙型肝炎病毒 (HBV) 感染的终末结果。需要早期预后标志物来进行有效的治疗并防止 HCC 的发生。蛋白质组学分析已被用于鉴定来自 HCC 患者的临床样本中的标志物。通过在 HCC 发生之前鉴定早期生物标志物，可以进一步改进这种方法。一种方法是使用基于细胞的 HBV 复制系统，该系统反映了病毒感染的早期阶段，因此在此阶段鉴定的分泌蛋白可能与 HCC 的预后相关。在本综述中，我们重点讨论细胞蛋白的蛋白质组学分析和 HCC 生物标志物鉴定的现状，特别强调基于细胞的 HBV 复制系统在鉴定预后 HCC 生物标志物方面的潜力。
